Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Judy L Shih

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Chest|February 3, 2011
Could vitamins be helpful to patients with sleep apnea?Judy L Shih, Atul Malhotra
Current Opinion in Pediatrics|May 19, 2009
Thyroid function in the critically ill newborn and childJudy L Shih, Michael S D Agus
American Journal of Ophthalmology|March 5, 2003
Peripheral keratitis associated with erythema elevatum diutinumAnthony J Aldave, Judy L Shih, Sayed Jovkar, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 4, 2009
Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidismMelanie Goldfarb, Patrick O'Neal, Judy L Shih, et al.
Molecular Biology of the Cell|July 21, 2005
Cell polarity protein Spa2P associates with proteins involved in actin function in Saccharomyces cerevisiaeJudy L Shih, Samara L Reck-Peterson, Rick Newitt, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 29, 2022
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trialPatrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2024
Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosisPaul McNally, Alvin Singh, Susanna A McColley, et al.
Cell Metabolism|April 10, 2009
Insulin signaling in alpha cells modulates glucagon secretion in vivoDan Kawamori, Amarnath J Kurpad, Jiang Hu, et al.
Lancet (London, England)|June 8, 2026
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trialVanita R Aroda, Melanie J Davies, Jill Maaske, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Chest|February 3, 2011
Could vitamins be helpful to patients with sleep apnea?Judy L Shih, Atul Malhotra
Current Opinion in Pediatrics|May 19, 2009
Thyroid function in the critically ill newborn and childJudy L Shih, Michael S D Agus
American Journal of Ophthalmology|March 5, 2003
Peripheral keratitis associated with erythema elevatum diutinumAnthony J Aldave, Judy L Shih, Sayed Jovkar, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|June 4, 2009
Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidismMelanie Goldfarb, Patrick O'Neal, Judy L Shih, et al.
Molecular Biology of the Cell|July 21, 2005
Cell polarity protein Spa2P associates with proteins involved in actin function in Saccharomyces cerevisiaeJudy L Shih, Samara L Reck-Peterson, Rick Newitt, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|December 29, 2022
Long-term tezacaftor/ivacaftor safety and efficacy in people with cystic fibrosis and an F508del-CFTR mutation: 96-week, open-label extension of the EXTEND trialPatrick A Flume, R Scott Harris, Hildegarde Paz-Diaz, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|April 5, 2024
Safety and efficacy of ivacaftor in infants aged 1 to less than 4 months with cystic fibrosisPaul McNally, Alvin Singh, Susanna A McColley, et al.
Cell Metabolism|April 10, 2009
Insulin signaling in alpha cells modulates glucagon secretion in vivoDan Kawamori, Amarnath J Kurpad, Jiang Hu, et al.
Lancet (London, England)|June 8, 2026
Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trialVanita R Aroda, Melanie J Davies, Jill Maaske, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 22, 2022
A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variantGregory S Sawicki, Mark Chilvers, John McNamara, et al.
Pageof 1